Abstract: The invention relates to the administration of von Willebrand factor (vWF)-containing drugs in association with the therapeutic use of blood anticoagulants, either on their own or together with fibrinolytics. The administration, which is for the purpose of reducing the risk of hemorrhages in patients, can take place either at the same time or following the anticoagulant and lytic treatment. A therapy principle is described which separates, during therapy, the desirable effect of anticoagulation and/or fibrinolysis from the undesirable side effect of hemorrhagic tendency.

Abstract: The invention relates to a method for determining platelet aggregation in the presence of an inhibitor of fibrin aggregation, which prevents the formation of an interfering fibrin clot, and to a diagnostic aid for determining the platelet aggregation-inhibiting action of thrombin inhibitors.

Abstract: Potent, specific inhibitors of phospholipase A.sub.2 are disclosed which are compounds of the formula: ##STR1## wherein A is R.sub.1 CO.sub.2 or OH, B is R.sub.2 CO.sub.2 or OH, D is R.sub.3 CO.sub.2 or OH and C is R.sub.4 CO.sub.2 ; and wherein R.sub.1, R.sub.2, and R.sub.3 and R.sub.4 are each C.sub.10 -C.sub.30 alkyl groups comprising from about 0-3 double bonds.